Non-small-cell lung cancer
Conditions
Interventions
Sponsors
Tochigi Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Histologically confirmed StageIIIB/IV non-small-cell lung cancer and non-squamous cell carcinoma. 2.Patients who have previously treated one chemotherapy regimen (without docetaxel and bevacizumab.). 3.With one or more measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) ver.1.1. 4.No chemotherapy within 21days No operation or radiotherapy within 56 days No pleurodesis, pleural drainage etc. within 28 days 5.Age20<= 6.Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. 7.Adequate function of vital organs, including normal hematopoietic function, normal liver function and normal renal function as evidenced by the following data: 8.A life expectancy of more than 3 months. 9.All patients provided written informed consent before initiation of study-related procedures.
Exclusion criteria
Exclusion criteria: 1)Symptomatic Brain metastasis or expected bleeding. 2) history of active double cancer within 5 years. 3) Severe infection 4) History of hemoptysis with 2.5mL or more. 5) Continued bloody phlegm. 6) Receiving anticoagulant drug(including Aspirin over 325mg/day). 7) Perforation of the digestive tract or history of the perforation of the digestive tract within the past one year. 8) Severe comorbidity (heart failure Tendency to hemorrhages uncontrollable hypertension, uncontrollable diabetes, etc) 9) Arterial thromboembolism and Venous thromboembolism within the past one year. 10)Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 11) Neuropathy or edema 12) History of hypersensitivity reaction to drugs formulated with polysorbate. 13) Planning of surgery or thoracic radiotherapy during the trial. 14) Major surgical procedure 15) With a history of drug sensitivity. 16) Pregnant or lactating women or those who declined contraception. 17) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Response rate Overall survival Safety PFS,RR,OS,DCR(harboring EGFR mutation or not) | — |
Countries
Japan
Contacts
Public ContactTakashi Kasai
Tochigi Cancer Center Division of Thoracic Oncology
Outcome results
None listed